Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M

Aligos Therapeutics, Inc.

Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.
Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.
Tiered high single-digit royalties on net sales in the Territory.
Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.
Effectiveness conditional on Amoytop shareholder approval within 45 days of signing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aligos Therapeutics, Inc. entered into License Agreement with Xiamen Amoytop Biotech Co., Ltd. valued at $25 million (effective 2026-04-16).

Action: entry
Agreement: license
Counterparty: Xiamen Amoytop Biotech Co., Ltd.
Value: $25 million
Effective: 2026-04-16

Exact text from the filing

On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest

View on SEC.gov

Browse all material agreements →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-166987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.